Aktiedagen Stockholm – May 2, 2022

Sedermeradagen – April 25, 2022

AP1189

A Novel and First-in-Class Agent to Target the Melanocortin System

Our lead drug candidate AP1189, a once-daily oral selective melanocortin agonist, specifically stimulates melanocortin receptors – a distinct mode of action compared to approved anti-inflammatory drugs which can be immunosuppressive.  SynAct is currently evaluating AP1189 in rheumatoid arthritis (RA), in idiopathic membranous nephropathy (iMN, an autoimmune disease associated with the development of nephrotic syndrome) and in the treatment of respiratory insufficiency caused by COVID-19 infection.

A MESSAGE FROM OUR CEO

"A strong 2021 and prospects for an even stronger 2022"